Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EKLV | ISIN: US35168W1036 | Ticker-Symbol:
NASDAQ
04.06.25 | 21:59
1,970 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FRACTYL HEALTH INC Chart 1 Jahr
5-Tage-Chart
FRACTYL HEALTH INC 5-Tage-Chart

Aktuelle News zur FRACTYL HEALTH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiFractyl Health, Inc.: Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide1
19.05.Fractyl Health advances gene therapy for diabetes treatment1
19.05.Fractyl Health treibt Gentherapie für Diabetesbehandlung voran2
19.05.Fractyl Health, Inc.: Fractyl Health Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes141First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1TM gene therapy for patients with inadequately controlled T2D and obesity Expect...
► Artikel lesen
19.05.FRACTYL HEALTH, INC. - 8-K, Current Report2
17.05.Fractyl Health, Inc.: Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 202587Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D- potentially simultaneously addressing durability, adherence...
► Artikel lesen
FRACTYL HEALTH Aktie jetzt für 0€ handeln
14.05.Fractyl Health Partners with Forge for Rejuva Gene Therapy Development1
14.05.Fractyl signals accelerated enrollment for REMAIN-1 study while advancing Rejuva clinical milestones1
13.05.Fractyl Health, Inc.: Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates324REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1...
► Artikel lesen
13.05.FRACTYL HEALTH, INC. - 10-Q, Quarterly Report1
28.04.Fractyl Health, Inc.: Fractyl Health to Present Compelling Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting2
02.04.Fractyl Health, Inc. (GUTS): Insider Were Buying In Q1 20251
01.04.FRACTYL HEALTH, INC. - 8-K, Current Report1
13.03.FRACTYL HEALTH, INC. - 8-K, Current Report-
09.03.Fractyl Health, Inc. Common Stock (NASDAQ:GUTS) Q4 2024 Earnings Call Transcript1
03.03.Fractyl Health, Inc. Loss At -$24.97 Mln In Q4-
03.03.Fractyl Health GAAP EPS of -$0.52 misses by $0.183
03.03.Fractyl Health, Inc.: Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates26Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full...
► Artikel lesen
03.03.FRACTYL HEALTH, INC. - 10-K, Annual Report-
03.02.Fractyl Health announces layoffs as it pivots to gene therapy2
Seite:  Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1